SA Asks: What are the most attractive biotech stocks right now?

[Genetic research and Biotech science Concept. Human Biology and pharmaceutical technology]
jittawit.21

What are the most attractive biotech stocks right now for investors?

Seeking Alpha analysts Stephen Ayers [https://seekingalpha.com/author/stephen-ayers] and Petri Dish Reports [https://seekingalpha.com/author/petri-dish-reports] offer their picks.

Stephen Ayers [https://seekingalpha.com/author/stephen-ayers]: A few names currently stand out to me. They have either recently launched drugs or are preparing to launch them.

I like what Insmed (INSM [https://seekingalpha.com/symbol/INSM]) is doing with Brinsupri in non-cystic fibrosis bronchiectasis, or NCFB. NCFB is what you would call a “greenfield” market, with limited treatment options and a high unmet need. In its pipeline, TPIP (a Phase 3 once-daily treprostinil palmitil inhalation powder) has the potential to leapfrog more frequently administered treprostinil formulations like United Therapeutics’ (UTHR [https://seekingalpha.com/symbol/UTHR]) Tyvaso DPI in blockbuster indications like pulmonary arterial hypertension, or PAH, and pulmonary hypertension associated with interstitial lung disease, or PH-ILD.

Cogent Biosciences (COGT [https://seekingalpha.com/symbol/COGT]) is readying a launch of bezuclastinib for systemic mastocytosis and gastrointestinal stromal tumors. Its opportunity in non-advanced systemic mastocytosis is particularly intriguing because bezuclastinib's improved tolerability profile over Sanofi’s (SNY [https://seekingalpha.com/symbol/SNY]) Ayvakit (another TKI) could meaningfully expand this market.

I also think there is still some “alpha” in the small-cap obesity arena. Structure Therapeutics (GPCR [https://seekingalpha.com/symbol/GPCR]) is one that I am watching closely, especially as it now trades well below Phase 2 data-inspired 52-week highs. The company is gearing up for a Phase 3 trial in obesity for its orally administered, once-daily, nonpeptide small molecule agonist of the glucagon-like-peptide-1 (GLP-1) receptor, aleniglipron.

Although a couple of oral treatments already exist in this market, like Novo Nordisk’s (NVO [https://seekingalpha.com/symbol/NVO]) Wegovy (a peptide) and Eli Lilly’s (LLY [https://seekingalpha.com/symbol/LLY]) Foundayo (a small molecule), I believe Structure’s aleniglipron has the capability to offer the “best of both worlds” with superior manufacturability and distinguished tolerability.

Petri Dish Reports [https://seekingalpha.com/author/petri-dish-reports]: A name generating a lot of attention is ImmunityBio (IBRX [https://seekingalpha.com/symbol/IBRX]). Here, the story is pretty much centered around their bladder cancer therapy, Anktiva. We’re seeing regulatory momentum following its FDA approval for non-muscle invasive bladder cancer, with the focus now shifting to commercialization and label expansion. The stock is up about 270% year-to-date. What makes the company particularly interesting to me is that it isn’t a hopeful Phase 2 story, but rather a revenue-generating biotech with a lot of potential upside from additional indications.

Travere Therapeutics (TVTX [https://seekingalpha.com/symbol/TVTX]) would be an undervalued pick. This is really a regulatory/data-driven story centered around Filspari. The drug received accelerated approval for IgA nephropathy, but I see major catalyst momentum tied to their confirmatory Phase 3 data and potential full approval. I also see upside from expansion into the kidney disease focal segmental glomerulosclerosis, which is a pretty large, underserved market. The data so far have shown meaningful proteinuria reduction.

One last name also worth a look is Relay Therapeutics (RLAY [https://seekingalpha.com/symbol/RLAY]). This is more of a pure clinical momentum play with their lead candidate, RLY-2608, a PI3Kα inhibitor, generating a lot of interest based on early-stage trial data, particularly in breast cancer combinations. I think the excitement is less about near-term FDA decisions and more about the emerging clinical data starting to validate their structure-based drug design platform. If those early datasets start to show stronger efficacy signals, we should see sharp moves because the upside case expands quickly if the mechanism proves out.

MORE ON STATE STREET® SPDR® S&P® BIOTECH ETF, ISHARES BIOTECHNOLOGY ETF

* Biotech Is Holding Steady In 2026 [https://seekingalpha.com/article/4888129-biotech-holding-steady-in-2026]
* The Private Credit Crack Up Gathers Momentum [https://seekingalpha.com/article/4882710-the-private-credit-crack-up-gathers-momentum]
* XBI: Biotech M&A Has Been Hot, But Price Trends Have Cooled [https://seekingalpha.com/article/4882403-xbi-biotech-m-and-a-has-been-hot-but-price-trends-have-cooled]
* Prediction-market traders put hantavirus pandemic risk at just 9% [https://seekingalpha.com/news/4590611-prediction-market-traders-put-hantavirus-pandemic-risk-at-just-9]
* Eli Lilly nears $2B-plus deal for Kelonia to expand cancer pipeline: WSJ [https://seekingalpha.com/news/4576388-eli-lilly-nears-2b-plus-deal-for-kelonia-to-expand-cancer-pipeline-wsj]